Comparative analysis of cardiomyopathy patients in the waiting list for heart transplantology treatment results depending on a disease etiology and a selected method of treatment

  • A. V. Gabriyelyan State Institute “Shalimov’s National Institute of Surgery and Transplantation” to National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
Keywords: chronicle heart failure, ischemic cardiomyopathy, dilated cardiomyopathy

Abstract

Introduction. In the paper we have conducted the efficiency evaluation of complex correction of heart pump function for patients with congestive heart failure (CHF) and patients with decreased left ventricular contractility being in the waiting list for heart transplantation, with continued 1-year long prospective observation.

Purpose. To analyze the treatment results of patients with cardiomyopathy being in the waiting list for heart transplanta-tion depending on disease etiology and conducted method of treatment.

Materials and Methods. We have reviewed the results of 1-year prospective observation, including 166 patients with CHF against the background of Ischemic Cardiomyopathy (ICMP) (113 p.) or Dilated Cardiomyopathy (DCMP) (53 p.), being in the waiting list for heart transplantation. In the DCMP group, the Batisa left venticuloplasty (33 p.) and Cord Blood Stem Cells Transplantation (CBSCT (20 p.) transplantation has been performed. In the ICMPIC group 38 patients went through Coronary Artery Bypass Grafting (CABG), 35 – Coronary Artery Stenting (CAS), 20 patients in addition to revasculariza-tion, went through CBSCT. The separate group of 20 people with the conservative therapy has been designated. Statistical data processing has been carried out.

Results and Discussion. Conducting the surgical correction of heart pump function for patients with ICMP, survival rate over the 1 year increased 1.636 and 1.667 times when conservative treatment supplemented with surgical one (CABG and CAS), and 6.0 times when conservative treatment supplemented with CABG. The effectiveness of complex therapy ICMP with the addition of Stem Cells has been revealed, 10% decrease of cardiovascular and general mortality has been proved over the group with conservative therapy, 18.9% mortality decrease compared to CABG, 18.6% – compared to Stenting. It has been proved, that 1-year mortality over the patients with DCMP decreases 15% while supplementing conservative treat-ment with CABG. On the other hand, the Batisa left venticuloplasty 1-year mortality results were unsatisfactory.

Conclusion. Complex differentiated approach towards the correction of left ventricular heart pump function for patients with different forms of Cardiomyopathy facilitates a likely decrease of CHF, increase of myocardium contractility, improve patient quality of life and can be used as a bridge to heart transplantation.

References

  1. liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiology Clinics. 2014;32:1–8. https://doi.org/10.1016/j.ccl.2013.09.009
  2. Kenchaiah S, Vasan RS. Heart Failure in Women--Insights from the Framingham Heart Study. Cardiovasc. Drugs Ther. 2015 Aug;29(4):377–90. https://doi.org/10.1007/s10557-015-6599-0
  3. Brangerand P, Samuel U, editors (Eurotransplant International Foundation). Annual report 2018. Leiden:Eurotransplant Foundation; III., graf., tab; 2019 May. Available from: https://www.eurotransplant.org/cms/index.php?page=annual_reports
  4. Anavekar NS, Chareonthaitawee P, Narula J, Gersh BJ. Revascularization in Patients With Severe Left Ventricular Dysfunction: Is the Assessment of Viability Still Viable? JACC. 2016;67(24):2874–87. https://doi.org/10.1016/j.jacc.2016.03.571
  5. Jolic?ur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC, et al. Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction Insights From STICH. JACC. 2015;66(19):2092–100. https://doi.org/10.1016/j.jacc.2015.08.882
  6. Chachques JC. Cardiomyoplasty: Is it still a viable option in patients with end-stage heart failure? European Journal of Cardio Thoracic Surgery. 2009; 35 (2): 201–3. https://doi.org/10.1016/j.ejcts.2008.09.028
  7. Vrtovec B. Cell Therapy for Nonischemic Cardiomyopathy: Current Status and Future Perspectives. Circ Res. 2018;122(1):28–30. https://doi.org/10.1161/CIRCRESAHA.117.312385
  8. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews. 2016;12:CD007888. https://doi.org/10.1002/14651858.CD007888.pub3
  9. Medhekar SK, Shende VS, Chincholkar AB. Recent Stem Cell Advances: Cord Blood and Induced Pluripotent Stem Cell for Cardiac Regeneration – a Review. International Journal of Stem Cells. 2016;9(1):21–30. https://doi.org/10.15283/ijsc.2016.9.1.21
  10. Dzholdasbekova A, Fedotovskikh G, Askarov M, Komsabakova B, Baigenzhina A, Kairatova A, et al. [Systemic administration of autologous mononuclear precultured bone marrow stem cells in heart failure]. Clinical Medicine of Kazakhstan. 2015;3(37):14–18. Russian.
Published
2019-09-16
How to Cite
Gabriyelyan, A. V. (2019). Comparative analysis of cardiomyopathy patients in the waiting list for heart transplantology treatment results depending on a disease etiology and a selected method of treatment. Ukrainian Journal of Cardiovascular Surgery, (3 (36), 29-34. https://doi.org/10.30702/ujcvs/19.36/06(029-034)